Exportar registro bibliográfico


Metrics:

EUS-guided intragastric injection of botulinum toxin A in the preoperative treatment of super-obese patients: a randomized clinical trial (2019)

  • Authors:
  • USP affiliated authors: SANTO, MARCO AURELIO - FM
  • Unidades: FM
  • DOI: 10.1007/s11695-018-3470-y
  • Subjects: ENZIMAS PROTEOLÍTICAS; OBESIDADE; ESVAZIAMENTO GÁSTRICO; ENDOSCOPIA DO SISTEMA DIGESTÓRIO; ULTRASSONOGRAFIA
  • Language: Inglês
  • Imprenta:
  • Source:
  • Online source accessDOI
    Informações sobre o DOI: 10.1007/s11695-018-3470-y (Fonte: oaDOI API)
    • Este periódico é de assinatura
    • Este artigo NÃO é de acesso aberto
    • Cor do Acesso Aberto: closed

    How to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      MOURA, Eduardo Guimaraes Hourneaux de; RIBEIRO, Igor Braga; FRAZAO, Mariana Souza Varela; et al. EUS-guided intragastric injection of botulinum toxin A in the preoperative treatment of super-obese patients: a randomized clinical trial. Obesity surgery, New York, v. 29, n. 1, p. 32-39, 2019. Disponível em: < http://observatorio.fm.usp.br/handle/OPI/30846 > DOI: 10.1007/s11695-018-3470-y.
    • APA

      Moura, E. G. H. de, Ribeiro, I. B., Frazao, M. S. V., Mestieri, L. H. M., Moura, D. T. H. de, Bo, C. M. R. D., et al. (2019). EUS-guided intragastric injection of botulinum toxin A in the preoperative treatment of super-obese patients: a randomized clinical trial. Obesity surgery, 29( 1), 32-39. doi:10.1007/s11695-018-3470-y
    • NLM

      Moura EGH de, Ribeiro IB, Frazao MSV, Mestieri LHM, Moura DTH de, Bo CMRD, Brunaldi VO, Moura ETH de, Nunes GC, Bustamante FAC, Santo MA. EUS-guided intragastric injection of botulinum toxin A in the preoperative treatment of super-obese patients: a randomized clinical trial [Internet]. Obesity surgery. 2019 ; 29( 1): 32-39.Available from: http://observatorio.fm.usp.br/handle/OPI/30846
    • Vancouver

      Moura EGH de, Ribeiro IB, Frazao MSV, Mestieri LHM, Moura DTH de, Bo CMRD, Brunaldi VO, Moura ETH de, Nunes GC, Bustamante FAC, Santo MA. EUS-guided intragastric injection of botulinum toxin A in the preoperative treatment of super-obese patients: a randomized clinical trial [Internet]. Obesity surgery. 2019 ; 29( 1): 32-39.Available from: http://observatorio.fm.usp.br/handle/OPI/30846

    Referências citadas na obra
    Kumar N, Thompson CC. Endoscopic solutions for weight loss. Curr Opin Gastroenterol 2011. p. 407–11.
    Svanevik M, Risstad H, Hofsø D, et al. Perioperative outcomes of proximal and distal gastric bypass in patients with BMI ranged 50–60 kg/m2—a double-blind, randomized controlled trial. Obes Surg. 2015;25:1788–95.
    Ribeiro IB, Gestic MA, Utrini MP, et al. Drain amylase levels may indicate gastrojejunostomy leaks after Roux-en-Y gastric bypass. Arq Gastroenterol, Available from. 2018;55:66–72. http://www.ncbi.nlm.nih.gov/pubmed/29561980.
    Flum DR, Dellinger EP. Impact of gastric bypass operation on survival: a population-based analysis. J Am Coll Surg. 2004;199:543–51.
    Madruga Neto AC, Bernardo WM, de Moura DT, et al. The effectiveness of endoscopic gastroplasty for obesity treatment according to fda thresholds: systematic review and meta-analysis based on randomized controlled trials. Gastrointest Endosc. 2018;87:AB601. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0016510718325690.
    Forlano R, Ippolito AM, Iacobellis A, et al. Effect of the BioEnterics intragastric balloon on weight, insulin resistance, and liver steatosis in obese patients. Gastrointest Endosc. 2010;71:927–33.
    Herve J, Wahlen CH, Schaeken A, et al. What becomes of patients one year after the intragastric balloon has been removed? Obes Surg. 2005;15:864–70.
    de Moura EGH, Martins BC, Lopes GS, et al. Metabolic improvements in obese type 2 diabetes subjects implanted for 1 year with an endoscopically deployed duodenal–jejunal bypass liner. Diabetes Technol Ther. 2012;14:183–9. https://doi.org/10.1089/dia.2011.0152 .
    Ribeiro IB, Rezende DT, Madruga Neto AC, et al. Endoscopic dual therapy for giant peptic ulcer hemorrhage. Endoscopy. 2018:1–2. https://doi.org/10.1055/a-0665-4142 .
    Hallett M, Albanese A, Dressler D, Segal KR, Simpson DM, Truong D, et al. Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders. Toxicon. 2013;94–114.
    Rhee P-L, Lee JY, Son HJ, et al. Analysis of pacemaker activity in the human stomach. J Physiol. 2011;589:6105–18. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22005683.
    Xing J, Chen JDZ. Alterations of gastrointestinal motility in obesity. Obes Res; 2004. p. 1723–32.
    Gui D, De Gaetano A, Spada PL, et al. Botulinum toxin injected in the gastric wall reduces body weight and food intake in rats. Aliment Pharmacol Ther. 2000;14:829–34.
    Bessesen DH, Van Gaal LF. Progress and challenges in anti-obesity pharmacotherapy. Lancet Diabetes Endocrinol. 2018;6:237–48. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28919062.
    Syed MI, Morar K, Shaikh A, et al. Gastric Artery Embolization Trial for the Lessening of Appetite Nonsurgically (GET LEAN): six-month preliminary data. J Vasc Interv Radiol. 2016;27:1502–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27567998.
    Cha R, Marescaux J, Diana M. Updates on gastric electrical stimulation to treat obesity: systematic review and future perspectives. World J Gastrointest Endosc. 2014;6:419–31. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25228944.
    Cullen JJ, Kelly KA. Gastric motor physiology and pathophysiology. Surg Clin North Am. 1993;73:1145–60. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8248831.
    Orsini M, Leite MAA, Chung TM, et al. Botulinum neurotoxin type A in neurology: update. Neurol Int. 2015;7:31–5.
    Pirazzini M, Rossetto O, Eleopra R, et al. Botulinum neurotoxins: biology, pharmacology, and toxicology. Pharmacol Rev. 2017;69:200–35. https://doi.org/10.1124/pr.116.012658 .
    Schiavo G, Rossetto O, Benfenati F, et al. Tetanus and botulinum neurotoxins are zinc proteases specific for components of the neuroexocytosis apparatus. Ann N Y Acad Sci. 1994;710:65–75.
    Wheeler A, Smith HS. Botulinum toxins: mechanisms of action, antinociception and clinical applications. Toxicol Elsevier Ireland Ltd. 2013;306:124–46. Available from:. https://doi.org/10.1016/j.tox.2013.02.006 .
    Jankovic J. Botulinum toxin: state of the art. Mov Disord. 2017;32:1131–8.
    Meunier FA, Schiavo G, Molgó J. Botulinum neurotoxins: from paralysis to recovery of functional neuromuscular transmission. J Physiol Paris. 2002. p. 105–13.
    Dashtipour K, Pedouim F. Botulinum toxin: preparations for clinical use, immunogenicity, side effects, and safety profile preparations for clinical use. Semin Neurol. 2016;36:29–33.
    Jankovic J. Botulinum toxin: state of the art. Mov Disord. 2017. p. 1131–8.
    Atassi MZ. Basic immunological aspects of botulinum toxin therapy. Mov Disord. 2004;19:S68–84.
    Albanese A, Bentivoglio Ar, Cassetta E, Viggiano A, Maria G, Gui D. Review article: the use of botulinum toxin in the alimentary tract. Aliment Pharmacol Ther 1995;9:599–604.
    Coskun H, Duran Y, Dilege E, et al. Effect on gastric emptying and weight reduction of botulinum toxin-A injection into the gastric antral layer: an experimental study in the obese rat model. Obes Surg. 2005;15:1137–43.
    Mittermair R, Keller C, Geibel J. Intragastric injection of botulinum toxin A for the treatment of obesity. Obes Surg. 2007;17:732–6.
    Foschi D, Lazzaroni M, Sangaletti O, et al. Effects of intramural administration of botulinum toxin A on gastric emptying and eating capacity in obese patients. Dig Liver Dis. 2008;40:667–72.
    Topazian M, Camilleri M, Enders FT, et al. Gastric antral injections of botulinum toxin delay gastric emptying but do not reduce body weight. Clin Gastroenterol Hepatol. 2013;11:145–150.e1.
    Gui D, Mingrone G, Valenza V, et al. Effect of botulinum toxin antral injection on gastric emptying and weight reduction in obese patients: a pilot study. Aliment Pharmacol Ther. 2006;23:675–80.
    Vargas EJ, Rizk M, Bazerbachi F, et al. Medical devices for obesity treatment: endoscopic bariatric therapies. Med Clin North Am, Available from. 2018;102:149–63. http://www.ncbi.nlm.nih.gov/pubmed/29156183.
    Brunaldi VO, Jirapinyo P, de Moura DTH, et al. Endoscopic treatment of weight regain following Roux-en-Y gastric bypass: a systematic review and meta-analysis. Obes Surg Obesity Surgery. 2017:1–11.
    Neto MG, Silva LB, Grecco E, et al. Brazilian Intragastric Balloon Consensus Statement (BIBC): practical guidelines based on experience of over 40,000 cases. Surg Obes Relat Dis. 2018;14:151–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29108896.
    Ribeiro IB, Bernardo WM, Martins C, et al. Colonic stent versus emergency surgery as treatment of malignant colonic obstruction in the palliative setting: a systematic review and meta-analysis. Endosc Int Open. 2018;5:1–10.
    McMenamin CA, Travagli RA, Browning KN. Inhibitory neurotransmission regulates vagal efferent activity and gastric motility. Exp Biol Med (Maywood). 2016;241:1343–50. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27302177.
    Rollnik JD, Meier PN, Manns MP, et al. Antral injections of botulinum a toxin for the treatment of obesity. Ann Intern Med. 2003;138:359–60. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12585845.
    Sahebally SM, Meshkat B, Walsh SR, et al. Botulinum toxin injection vs topical nitrates for chronic anal fissure: an updated systematic review and meta-analysis of randomized controlled trials. Colorectal Dis. 2018;20:6–15. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29166553.
    Dorizas A, Krueger N, Sadick NS. Aesthetic uses of the botulinum toxin. Dermatol Clin. 2014. p. 23–36.
    Gart MS, Gutowski KA. Overview of botulinum toxins for aesthetic uses. Clin Plast Surg; 2016. p. 459–71.
    Chagas TF, de Almeida NV, Lisboa CO, et al. Duration of effectiveness of botulinum toxin type A in excessive gingival display: a systematic review and meta-analysis. Braz Oral Res. 2018;32:1–11. Available from: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1806-83242018000100951&lng=en&tlng=en.
    Bustamante F, Brunaldi VO, Bernardo WM, et al. Obesity treatment with botulinum toxin-A is not effective: a systematic review and meta-analysis. Obes Surg Obesity Surgery. 2017;27:2716–23.
    Elshakh H, El-Ejji K, Taheri S. The role of endoscopic intra-gastric botulinum toxin-A for obesity treatment. Obes Surg Obesity Surgery. 2017;27:2471–8.
    Sánchez Torralvo FJ, Valdés Hernández S, Tapia MJ, Abuín Fernández J, Olveira G. Inyección intragástrica de toxina botulínica mediante endoscopia, ¿una alternativa para el tratamiento para la obesidad? Una revisión sistemática. Nutr Hosp. 2017; Available from: http://revista.nutricionhospitalaria.net/index.php/nh/article/view/1220.
    Lerner H, Whang J, Nipper R. Benefit-risk paradigm for clinical trial design of obesity devices: FDA proposal. Surg Endosc. 2013;27:702–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23247746.
    Oficial Ó, Federación DELA, Sociedades EDE, et al. Nutr Hosp. 2015;31:1–145.

Digital Library of Intellectual Production of Universidade de São Paulo     2012 - 2020